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ABSTRACT 
      Prostate cancer is the second most common cancer in men. In spite of on-going researches in this 
filed, the specific causes of prostate cancer are so far unknown. In this study, we used two methods of 
Gene Set Analysis to improve the biological interpretation of the observed expression patterns in 
prostate cancer. The Gene Set Analysis is a computational method to discover gene sets whose 
expression is associated with a phenotype of interest. In addition, we used these methods to search gene 
sets defined by KEGG and BioCarta. Although, our results showed that most of the gene sets were 
associated with prostate cancer in the Category and Hotelling’s T
2
 methods, the power of the Hotelling’s 
T
2
 was more than Category method in either KEGG or BioCarta gene sets. The concordance between the 
results of Pubmed articles and KEGG gene sets was more than the results of Pubmed articles and 
BioCarta gene sets. 
 





Prostate cancer is a form of cancer that develops 
in the prostate, a gland in the male reproductive 
system. Although most prostate cancers are 
slow growing, there are cases of aggressive 
prostate cancers [1]. Prostate cancer is the 
second most common cancer in men and the 
fifth in both sexes combined. However, 14% of 
all new male cancer cases have been related to 
this cancer, in the world [2]. In Iran, the 
incidence rate of prostate cancer was 5.1 per 
100,000 person-years [3].  In spite of on-going 
researches in this filed, the specific causes of 
prostate cancer are so far unknown [4].  
The integration of biology and statistics 
sciences in Gene Set Analysis (GSA) has been 
transformed into a strong arm which enables 
researchers to assay differential gene expression 
for finding related biomarkers. A gene set is a 
group of genes that is defined based on prior 
biological knowledge on gene functions 
available from public databases such as Kyoto 
Encyclopedia of Genes and Genomes 
(KEGG)[5], BioCarta [6] and Gene Ontology 
(GO)[7]. The discovery of biomarker based on 
differentially expressed gene set rather than 
individual gene increases statistical power and 
enhances interpretability and more direct 
biological meaning.  
Many statistical approaches have been proposed 
to accomplish GSA methods. Some of them 
calculate the gene set statistic based on gene 
level statistic [8-12]. Another group of GSA 
methods used of multivariate techniques to 
calculate gene set statistic [13-14]. In this study, 
two GSA methods, the Category [8] and 
Hotelling’s T
2 
[9], were utilized to identify the 
gene sets defined by the KEGG and BioCarta, 
which were strongly associated with prostate 
cancer.  
 
MATERIAL AND METHODS 
Category method 
The Category method is the rich extension of 
GSA methods. In this method, t-statistic for all 
genes in the dataset is calculated as gene level 
statistic. The mean of the absolute t-statistics 










Where ti is the t-statistic for the ith gene and m 
is the number of genes in a gene set. This idea 
that the changes of gene expressions in each 




gene set is either up or down regulated seems 
not to be true, thus we preferred to use the 
absolute t-statistics instead of t-statistics. The 
subject sampling has been used to determine 
permutation p-values.  The subject sampling 
takes the subject (sample) as the sampling unit 
[8, 15]. The Category package in Bioconductor 
implements this method. The correlation 
structures within each set were not considered 
in this method because the set level statistic is 





 statistic tested the hypothesis
210
~~:H  , if F1 and F2 are multivariate 
normal distributions with common covariance 
matrix. Let m denote the number of genes in a 
gene set, ni denote sample size for ith phenotype 
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(2) 
where V is the covariance matrix of the gene 
expression and 𝑋 𝑖  is the m-vector of means for 
the ith phenotype. 
One of the important problems in a gene 
expression study is that the number of sample is 
always much less than the number of gene. For 
this reason, to calculate the inverse of 
covariance matrix, one needs to use additional 
steps. Tsai and Chen used the shrinkage 
estimator to calculate the inverse of covariance 
matrix [13]. The shrinkage covariance matrix 
estimator (𝑉𝑖𝑗
∗ ) proposed by Schafer and 

























Where vii and rij, respectively, denote the 
empirical sample variance and sample 
correlation, and the optimal shrinkage intensity 















̂        (5). 
 
Moreover, this method took account either the 
correlation structure among genes or both up- 
regulated and down-regulated gene expressions. 
The permutation p-values were calculated based 
on subject sampling in this package.  
Datasets 
The prostate cancer dataset was downloaded 
from Gene Expression Omnibus (GEO). This 
dataset which hybridized to affymetrix human 
genome HG-U133A platform consists of a total 
RNA from 148 prostate samples with various 
percentages of tumors determined by 
pathologist [15]. 12 samples whose percentage 
of tumor was not registered were excluded and 
the other samples were all included in the 
processing. We divided 136 samples based on 
percentage of tumor into two groups, tumor 
(n=65) and non-tumor (n=71). The percentage 
of tumor range 0 to 0.1 in tumor group and 0.1 
to 0.8 in another group.  The null hypothesis 
tested here is various percentages of tumors 
with respect to their overall gene expression 
pattern. There are 22,283 probe sets in this 
platform.  
The normalization of microarray data by the 
robust multi-array average (RMA) [18] 
algorithm was implemented using the 
Babelomics suite (an integrated web tool for 
microarray data analysis and functional 
profiling of genome-scale experiments) [19]. 
The Babelomics was also used to categorize 
22,283 probe sets to 106 KEGG gene sets and 
312 BioCarta gene sets. The KEGG and 
BioCarta gene sets contained 2,665 and 2,046 
probe sets, respectively. Hence a high number 
of probes on the prostate cancer lacked gene set. 
We revealed differentially expressed KEGG and 
BioCarta gene sets between tumor and non-






     In this research, we found that 1,303 probe 
sets out of 2,665 related KEGG were 
statistically different, while 928 probe sets out 
of 2,046 probe related BioCarta were 
statistically different between tumor and non-
tumor samples.  
The Hotelling’s T
2
 method revealed that 105 
KEGG gene sets were significant (p-values less 
than 0.05), while 65 KEGG significant gene sets 
were observed in the Category method. The top 
ten KEGG significant gene sets for two methods 
were shown in table 1.  
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Table 1. The KEGG gene sets with p < 0.05 by the two GSA methods in the prostate cancer dataset. 
 
In BioCarta, the Hotelling’s T
2
 method showed 
that 312 gene sets were significant (p-values 
less than 0.05), while 54 significant gene sets 
were observed in the Category method. The top 
ten BioCarta significant gene sets by the two 






Size KEGG Gene Set 
Category 
0.000 -6.99515 10 DNA replication 1 
0.000 -8.83720 12 Mismatch repair 2 
0.000 -8.26923 47 Primary immunodeficiency 3 
0.000 -12.9652 57 One carbon pool by folate 4 
0.000 -7.46058 13 Tryptophan metabolism 5 
0.000 -7.60349 35 Renin-angiotensin system 6 
0.000 -10.11030 20 Base excision repair 7 
0.000 -5.99054 19 Limonene and pinene degradation 8 
0.002 -9.54988 39 Primary bile acid biosynthesis 9 
0.002 -3.71500 4 Riboflavin metabolism 10 
Hotelling’s T2 
0.000 511.077790 75 Nitrogen metabolism 1 
0.000 506.142051 69 Arginine and proline metabolism 2 
0.000 480.856398 86 Drug metabolism - other enzymes 3 
0.000 477.615468 68 Glyoxylate and dicarboxylate metabolism 4 
0.000 470.832097 78 Starch and sucrose metabolism 5 
0.000 447.099907 70 Glycosphingolipid biosynthesis 6 
0.000 444.186458 78 mTOR signaling pathway 7 
0.000 427.867381 80 Pentose phosphate pathway 8 
0.000 423.784298 84 Caffeine metabolism 9 
0.000 419.313996 71 Linoleic acid metabolism 10 





Size BioCarta Gene Set 
Category 
0.000 13.82763 11 Integrin Signaling Pathway 1 
0.000 16.50176 37 
Role of PI3K subunit p85 in regulation of Actin Organization and 
Cell Migration 
2 
0.000 11.09129 29 Role of Erk5 in Neuronal Survival 3 
0.000 13.49084 24 IL12 and Stat4 Dependent Signaling Pathway in Th1 Development 4 
0.000 12.03878 26 VEGF, Hypoxia, and Angiogenesis 5 
0.000 12.19200 27 The information-processing pathway at the IFN-beta enhancer 6 
0.001 9.94616 24 
Inhibition of Huntington's disease neurodegeneration by histone 
deacetylase inhibitors 
7 
0.001 13.56122 26 Oxidative Stress Induced Gene Expression Via Nrf2 8 
0.001 10.24244 16 CXCR4 Signaling Pathway 9 
0.004 6.139434 12 Opposing roles of AIF in Apoptosis and Cell Survival 10 
Hotelling’s T2
 
0.000 336.0954 46 ALK in cardiac myocytes 1 
0.000 326.3753 39 Low-density lipoprotein (LDL) pathway during atherogenesis 2 
0.000 325.3372 44 Agrin in Postsynaptic Differentiation 3 
0.000 312.7743 55 Nuclear Receptors in Lipid Metabolism and Toxicity 4 
0.000 308.0685 37 Electron Transport Reaction in Mitochondria 5 
0.000 299.9156 53 Synaptic Proteins at the Synaptic Junction 6 
0.000 299.1207 32 Antigen Processing and Presentation 7 
0.000 296.0046 26 Ceramide Signaling Pathway 8 
0.000 292.5901 37 Role of BRCA1, BRCA2 and ATR in Cancer Susceptibility 9 
0.000 291.208 37 
Role of PI3K subunit p85 in regulation of Actin Organization and 
Cell Migration 
10 




We excluded genes present in more than 30 
gene sets in BioCarta. There were no 
relationships between them and prostate cancer 
in Pubmed literatures. The name of these genes 
has been listed in table 3. 
 
DISCUSSION 
     Prostate Cancer is one of the most 
challenging cancers in the medical field and its 
mechanism still remains completely unclear. 
There are more than 20 types of prostate cancer. 
No single theory can provide a perfect 
definition for different cases of this cancer. The 
GSA of microarray data not only shows a 
consistent alteration in a cancer state, but also is 
a valid method to reduce a major deviation. In 
addition, the GSA methods enable us to obtain 
common gene sets by integration differently ex-
pressed genes.  
Hence, we used the GSA methods for 
exploration of genes in prostate cancer which 
are difficult to detect by individual gene 
analysis because of their subtle change. In the 
present study, the Hotelling’s T
2
 and Category 
were applied to prostate cancer dataset to extract 
biological insights involved in this cancer by 
defined gene sets in KEGG and BioCarta. 
Our finding showed that the power of 
multivariate analysis (Hotelling’s T
2
) is more 
than univariate analysis (Category) in KEGG 
and BioCarta. These results were in agreement 
with published findings elsewhere [13, 27-28]. 
This conclusion is anticipated because the 
Hotelling’s T
2
 takes account the complicated 
correlation structure and interaction among 
genes, unlike the Category that is based on 
univariate analysis (t-statistics).   
Our results showed that most of the gene sets 
were associated with prostate cancer. According 
to GSA results, we discussed several 
differentially expressed gene sets and genes 
shared among gene sets which suggested the 
role of these gene sets and genes in prostate 
cancer. The concordance between the results of 
Pubmed articles and KEGG gene sets was more 
than BioCarta gene sets. 
Furthermore, prostate cancer pathway (ID 5215) 
and Transcriptional misregulation in cancers 
(ID 5202) are connected pathways with prostate 
cancer in KEGG. The Thyroid cancer which 
related pathways with Transcriptional 
misregulation in cancer was shown in table 1.  
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